Ratio Therapeutics, Inc.
Clinical trials sponsored by Ratio Therapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new PET tracer reveal the Body's immune battles? Results expected Dec 2026 (estimated)
-
Radioactive drug takes aim at Hard-to-Treat sarcoma
Disease control Recruiting nowThis early-phase trial is testing a radioactive drug called [Ac225]RTX-2358 in 30 adults with advanced soft tissue sarcoma that has come back or stopped responding to prior treatment. The drug is given as an IV injection once every 8 weeks for up to 6 doses. The main goals are to…
Phase 1 • Sponsor: Ratio Therapeutics, Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a new PET tracer reveal the Body's immune battles?
Knowledge-focused Recruiting nowThis early-stage trial is testing an experimental imaging agent that targets granzyme B, a protein released by immune cells during activity. The goal is to see how this tracer moves through the body and how much radiation it delivers, using PET/CT scans and blood samples. Up to 1…
Early phase 1 • Sponsor: Ratio Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC